Gene wiki review

Structure, biochemistry, and biology of PAK kinases

Rakesh Kumar a,b,* Rahul Sanawar b, Xiaodong Li c, Feng Li c,**

*Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, George Washington University, Washington, DC 20037, USA

bCancer Biology Program, Rajiv Gandhi Center of Biotechnology, Thiruvananthapuram 695014, India

cDepartment of Cell Biology, Key Laboratory of Medical Cell Biology, Chinese Ministry of Education, China Medical University, Shenyang 110122, China

A B S T R A C T

PAKs, p21-activated kinases, play central roles and act as converging junctions for discrete signals elicited on the cell surface and for a number of intracellular signaling cascades. PAKs phosphorylate a vast number of substrates and act by remodeling cytoskeleton, employing scaffolding, and relocating to distinct subcellular compartments. PAKs affect wide range of processes that are crucial to the cell from regulation of cell motility, survival, redox, metabolism, cell cycle, proliferation, transformation, stress, inflammation, to gene expression. Understandably, their dysregulation disrupts cellular homeostasis and severely impacts key cell functions, and many of those are implicated in a number of human diseases including cancers, neurological disorders, and cardiac disorders. Here we provide an overview of the members of the PAK family and their current status. We give special emphasis to PAK1 and PAK4, the prototypes of groups I and II, for their profound roles in cancer, the nervous system, and the heart. We also highlight other family members. We provide our perspective on the current advancements, their growing importance as strategic therapeutic targets, and our vision on the future of PAKs.

© 2016 Elsevier B.V. All rights reserved.

Abbreviations: PAK, p21-activated kinase; AID, auto-inhibitory domain; PBD, p21-binding domain.

*Correspondence to: R. Kumar, Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, George Washington University, 530 Ross Hall, 2300 Eye Street, NW, Washington, DC 20037, USA.

**Correspondence to: F. Li, Department of Cell Biology, China Medical University, No.77 Puhe Road, Shenyang North New Area, Shenyang 110122, China.

E-mail addresses: bcmrxk@gwu.edu (R. Kumar), fli@mail.cmu.edu.cn (F. Li).

http://dx.doi.org/10.1016/j.gene.2016.12.014

0378-1119/© 2016 Elsevier B.V. All rights reserved.
1. Introduction

The p21-activated kinases (PAKs) are serine/threonine kinases and were initially discovered as binding proteins of small GTPases (Manser et al., 1994). PAKs soon emerged as effectors of Cdc42 and Rac1 small GTPases (Martin et al., 1995; Knaus et al., 1995; Bagrodia et al., 1995). The PAK family consists of six members and divided into two groups, group I (PAK1, PAK2, and PAK3) and group II (PAK4, PAK5, and PAK6). PAK5 is sometimes referred to as PAK7. The PAK gene sequences and their structures are conserved from amoeba, yeast, Caenorhabditis elegans, Xenopus, to human. The PAK family represents a converging junction for discrete cell surface triggers and affects cytoskeleton remodeling, intracellular signaling, and gene expression (Vadlamudi and Kumar, 2003; Kumar and Li, 2016; Shao et al., 2016). The molecular functions of the PAK family are because of their intrinsic ability to directly phosphorylate effector substrates, physically translocate to distinct subcellular domains, employ scaffolding activity, and modulate target gene expression. These processes are crucial to a large number of cellular functions and many human diseases including cancer.

The initial phase of PAK research primarily focused on studying the role of PAKs as effectors of small GTPases in the context of dynamic remodeling of cytoskeleton motile structures (Sells and Chernoff, 1997; Bokoch, 2003). The next phase of research revealed a definitive contribution to human cancer (Kumar et al., 2006; Molli et al., 2009; Radu et al., 2014), with the first report of PAK1 signaling cascade conferring invasiveness to breast cancer cells in response to heregulin-beta1-mediated ErbB2 stimulation (Adam et al., 1998) and its overexpression in breast tumors (Vadlamudi et al., 2000). Around the same time, the PAK researchers also began to move into nuclear functions beginning from the observation that activated PAK1 translocates to the nucleus in human cells (Li et al., 2002), opening up an exciting frontier for PAKs. These developments together set the stage for exploring the significance of PAKs in many cellular processes that confer cancer phenotype, viz., invasion, metastasis, anti-apoptosis, drug resistance, angiogenesis, epithelial-to-mesenchymal transition, DNA damage repair, modulation of gene expression, and changes in progression of mitosis and cell cycle. PAKs are now known as crucial transducers for signals that originate on the membrane and ultimately confer cancer phenotypes (Fig. 1). The primary focus of the review is PAKs role in cancer, and we delve into PAKs various physiological processes and their significance in the nervous system and the heart. We choose PAK1 and PAK4, the prototypes of groups I and II, to give a detailed outline of the structure, biochemistry, and biology of PAK family. We also discuss other members PAK2, PAK3, PAK5, and PAK6.

2. PAK’s structural domains and mechanism of action

The PAK family contains an auto inhibitory domain (AID), a kinase domain at the carboxyl-terminus, and a p21-binding domain (PBD) at the amino-terminus. The AID domain in group I PAK partly overlaps with a modified AID domain in group II PAKs (Fig. 2). The regulatory domains of groups I and II are structurally distinct, and their activation processes are different (Lei et al., 2000). The kinase activity of group I PAKs is stimulated when bound to small GTPases or other proteins, but in group II PAKs, the kinase activity is constitutive. The mechanisms of PAK activation have been extensively reviewed before in several reviews (Rane and Minden, 2014; Jha and Strauss, 2012; Baker et al., 2014). Here we discuss the principles of PAK activation.

The activity of group I is modified via a reciprocal auto inhibitory mechanism of two PAK molecules acting as a dimer. The PBD domain overlapping with the AID domain binds to the kinase domain of another PAK molecule, and this homodimerization makes them inactive (Fig. 3). Binding of an activated small GTPase to the PBD domain and concomitant interaction with the proximal amino acids and phosphoinositide, trigger distinct changes in the conformation of the catalytic domain. This leads to dissociation of the AID domain from the kinase domain, induce further conformational changes in the dimerized molecules, phosphorylate both PAK molecules, and stimulate their kinase activity (Lei et al., 2000; Pirruccello et al., 2006; Buchwald et al., 2001; Strochlic et al., 2010). Upon binding to a substrate, kinase domain also become a monomer, and auto phosphorylation stabilizes the PAK molecule in the activated form. Interestingly, some in vitro studies show that the active PAK1 kinase could continue to remain as a dimer. This aspect of PAK1 activation in physiologically relevant settings awaits further research, and may potentially reshape PAK-directed therapeutic approaches, if proven correct. In addition, AID function could be antagonized by mechanisms independent of small GTPases. For example, group I PAKs are stimulated by interaction of its PXXP motif with the SH3 domain in signaling molecules (Galisteo et al., 1996; Puto et al., 2003), phosphorylation by 3-phospho-inositide dependent kinase-1, AKT and JAK (Bokoch, 2003; Zhou et al., 2003; Tao et al., 2011), and binding of phospholipids, exchange factor (β-PIX or SH3 proteins such as NCK1 (Zhou et al., 2003; Fryer et al., 2006) and GRB2 (Strochlic et al., 2010; Banerjee et al., 2002; Thiel et al., 2002; Bokoch et al., 1998; King et al., 2000; Howe and Juliano, 2000; Shin et al., 2013).

As oppose to group I PAKs, group II PAKs remain active constitutively and generally lack an AID domain (Fig. 3). However, recently PAK4 regulatory domain has been shown to contain an AID-like pseudosubstrate sequence that inactivates the kinase activity of Cdc42-bound PBD domain (Baskaran et al., 2012; Ha et al., 2012). It has been suggested that the binding of the PS domain to an SH3 motif-containing protein may help release the catalytic domain and allow stimulation of the PAK kinase activity (Ha et al., 2012). Although our understanding of the mechanisms of PAK activation has improved tremendously over the years, the turn-off mechanism of group II PAKs remains unclear.

3. PAK’s gene structure and splicing

The human PAK1 gene contains 23 exons, of which six exons are for 5′-UTR and seventeen encode protein (Fig. 4A). The 5′-UTR of PAK1 mRNA is differentially expressed. In humans, there are twenty transcripts, ranging from 308 bp to 3.7 kb, generated via alternative splicing. Among these transcripts, only twelve contain open-reading frames and encode ten proteins and two small polypeptides. Others eight are non-coding RNA transcripts ranging from 308 to 863 nucleotides. In contrast

Fig. 1. PAK stimulation by upstream signals contributes to phenotypic signaling through binding partners (BP) and phosphorylation of effector substrates. Representative PAK-regulated cancerous phenotypes include – cytoskeleton remodeling, cell motility, inhibition of apoptosis, DNA damage response, gene expression, transformation and invasion, deregulated cell cycle progression and metastasis (from left to the right).
Fig. 2. Structural domains of group I and group II PAKs. For PAK1, detail organization of polypeptide chain was shown. Numerals indicate residue numbers at the boundaries of various subdivisions. The N-terminal auto-regulatory region (70–149aa) and the kinase domain (272–523aa) are shown. The detailed substructure of the auto-regulatory region including overlapped PBD (p21-binding domain) and AID (auto-inhibitory domain) is shown in the expanded upper part of the PAK1 diagram. | indicates proline-rich region and indicates the interaction motif for PIX. For other PAKs, PBD, kinase domain, and proline-rich region are shown for each family member.

Fig. 3. Models of PAK activation. P21-activated kinases (PAKs) have a conserved carboxyl-terminal serine/threonine kinase domain with a single phosphorylation (P) site and an amino-terminal regulatory domain. The regulatory domain of group I PAKs (PAK1–3) contain PBD (p21-binding domain) and overlapped AID (auto-inhibitory domain), which is structurally distinct from that of group II PAKs (PAK4–6). There are two suggested models for PAK4 activation.
to human PAK1, murine Pak1 generates five transcripts, of which three
coding transcripts of 508 to 3.0 kb long, and the other two are non-coding
RNAs of about 900 nucleotides with retained-intron sequences.

The PAK2 gene contains 15 exons and one is for 5′-UTR, and the re-
main ing generate three transcripts. The PAK2 gene is much shorter
than PAK1, about 92.7 kb (Fig. 4B). Among PAK2 transcripts, two encode
proteins of 524 amino acids and 221 amino acids, and the third is a non-
coding transcript of 371 nucleotides long. The murine Pak2 gene gener-
ates two transcripts. A 5.7kb protein-encoding transcript for 524 amino
acids, and another 1.2kb non-coding RNA transcript.

The PAK3 gene is the largest among group I members (Fig. 4C). The
human PAK3 gene is 283-kb and contains 22 exons of which 6 are for
5′-UTR region, and generates 13 transcripts. Among these transcripts,
11 PAK3 transcripts are predicted to code for proteins of 181 to 580
amino acids, while two transcripts are non-coding RNAs. The murine Pak3
gene generates ten transcripts, which are predicted to encode pro-
teins with 544 amino acids and 559 amino acids, and four small polypeptides.

Group II PAKs have less number of exons compared to group I PAKs,
which highlights the structural differences between the two groups. The
human PAK4 is 57kb and has 13 exons (Fig. 4D). There are 12 transcripts
in human, of which 10 transcripts encode predicted proteins of 438 to
591 amino acids, while there are two non-coding RNAs. The murine
Pak4 gene generates four transcripts. Two coding for proteins of 593
amino acids, and two others are non-coding with one RNA containing
retained-intron sequences.

The PAK5 (also known as PAK7) gene is about 301kb, much longer
than other PAKs, and contains 12 exons. Four for 5′-UTR, and eight exons
including eight for 5′-UTR and generates 17 transcripts. Fourteen
PAK6 transcripts encode four predicted proteins of 681 and 636 amino acids
(Fig. 4F), while remaining transcripts are non-coding. The murine
Pak6 gene yields five transcripts, of which two are predicted to encode
proteins of about 682 amino acids, and three others are non-coding in
nature.

Fig. 4. Structure and partial transcripts of human PAK genes. The diagram/table and transcripts of PAK1–6 genes are based on the ENSEMBL database (PAK1 ENSG00000149269, PAK2 ENSG00000180370, PAK3 ENSG00000177264, PAK4 ENSG00000130669, PAK5 ENSG00000101349, PAK6 ENSG00000137843). The blues are alternatively spliced coding exons and the
white ones are UTRs. The tables are based on the known protein coding transcripts, not including noncoding RNAs.
4. PAKs and cytoskeleton remodeling

The PAK signaling-initiated cytoskeleton remodeling plays an important role in cellular invasiveness and metastasis due to its phosphorylation of effector substrates and scaffolding (Fig. 5). For example, Cofilin-mediated depolymerization of F-actin is countered by increased ability of PAK1-phosphorylation of LIM-kinase-1 and regulation of its activity Cofilin on Ser3 (Edwards et al., 1999). Interestingly, activated LIMK1 leads to increased secretion of proteses that also have roles in breast cancer invasion (Bagheri-Yarmand et al., 2006), and remodeling of various components of the extracellular matrix (Scott et al., 2010). Similarly, PAK1, PAK4 and PAK5-signaling pathways affect MMP family of proteases in breast, ovarian, and glioma cancer cells (Hammer and Diakonova, 2015; Kesnakurti et al., 2012; Wang et al., 2013). PAK1 also contributes to cytoskeleton remodeling via actin depolymerization and nucleation. For example, the stability and nucleation activity of the Arp2/3 actin nucleation complex and its role in cancer cell motility are modulated by PAK 1 phosphorylation of ArpC1b-Thr21 (Vadlamudi et al., 2005a). PAK1 phosphorylation of microtubule destabilizing protein Stathmin inactivates its inhibitory activity against microtubule stabilization (Wittmann et al., 2004).

In recent years, similar to PAK1 signaling, there is a growing emphasis on PAK4 substrates with role in cytoskeleton reorganization and cell motility. PAK4 phosphorylates LIMK1 at Thr508 and regulates cell migration (Ahmed et al., 2008). Although PAK4 kinase activity is not stimulated by Cdc42, its interaction with activated Cdc42 is critical for cytoskeletal reorganization. PAK4-Cdc42 interaction has also been shown to support redistribution of PAK4 to the Golgi compartment in porcine endothelial cells (Abo et al., 1998). In addition, PAK4 also signals through LIMK1 and stabilizes actin–myosin filaments (Dan et al., 2001), while PAK4 phosphorylation of integrin β5 on Ser759 and Ser762 promotes cell migration (Li, Z. et al., 2010). Both PAK4 and PAK5 phosphorylate p120-catenin on Ser288 for cytoskeleton reorganization (Wong et al., 2010). Interestingly, PAK4 phosphorylation of superior cervical ganglia 10 (SCG10) facilitates dynamics of microtubules and invasiveness of cancer cells (Guo et al., 2014). PAK4 phosphorylation also inhibits GEF-H1-regulated stress fiber formation in fibroblasts (Callow et al., 2005) (Wells et al., 2010). In addition to its role in cytoskeleton remodeling, PAK4 reduces the level of cyclin-dependent kinase inhibitor p57(kip2) with implications in cell-cycle progression in breast cancer cell line (Li, Y. et al., 2013). Similarly, PAK4 phosphorylation of β-catenin on Ser675 contributes to its transcriptional function (Li, Y. et al., 2012), and Smad2 on Ser465 plays a role in tumorigenesis (Wang, C. et al., 2014).

5. PAKs nuclear functions

In addition to their roles in the cytoplasmic compartment, PAKs also play crucial roles in the nuclear compartment and participate in mitotic events and gene expression (Li et al., 2002; Kumar et al., 2006; Kumar and Li, 2016). Growth factor stimulation of cancer cells triggers redistribution of activated PAK1 to the nucleus in breast cancer cells (Singh et al., 2005). Once in the nucleus, PAK1 interacts with chromatin and modulates target gene expression such as PFK-M (muscle-type isoform), NFAT (Singh et al., 2005), and tissue factor (TF) (Sanchez-Solana et al., 2012). Interestingly, PAK1 signaling also modulates chromatin remodeling via phosphorylating MORC2 in cancer cells exposed to ionizing radiation (Li, D.Q. et al., 2012; Li, Y. et al., 2012). PAK1 phosphorylation of STAT5 transcription factor on Ser779 modulates its transcriptional activation in mammary epithelial cells during mammary gland differentiation (Wang et al., 2003) and in leukemogenesis in BCR-
Disease relevance of nuclear PAKs became known after observations showed a close relationship between the level of nuclear PAK1 and resistance to tamoxifen in breast cancer patients (Holm et al., 2006). Consequent to PAK1, other family members are also found to have significant roles in the nucleus and cancer. Nuclear PAK4 has been found in endometrial cancer in postmenopausal women (Siu et al., 2015). Recently, PAK4 has been shown to be methylated by lysine methyltransferase SETD6; and its interaction with SETD6 and β-catenin regulates β-catenin-target genes (Vershchin et al., 2016). Another PAK-signaling-mediated regulation of gene expression is PAK phosphorylation-dependent modulation of corepressor functions. For example, PAK1 phosphorylation of C-terminal binding protein 1 (CTBP1) on Ser158 promotes its nucleus-to-cyttoplasmic redistribution, relieving CTBP1’s corepressor activity on its target genes (Barnes et al., 2003; Thomas et al., 2015). Activated PAK1 also phosphorylates β-cell lymphoma-6 corepressor in the nuclei of colon cancer cells (Barros et al., 2012). Other examples of PAK1 phosphorylation-mediated regulation of corepressors include SNAIL-Ser246, which affects epithelial-to-mesenchymal transition (Yang et al., 2005), and SHARP-Ser3486/Thr468, which affects regulation of NOTCH target genes (Vadlamudi et al., 2005a, 2005b). In growth factor-stimulated cancer cells, PAK1 phosphorylation of polyC-RNA binding protein 1 (PCBP1) at Thr60/Thr127 promotes its nuclear translocation. PCBP1 activates transcription of eukaryotic translation initiation factor 4E (Meng et al., 2007).

6. PAKs and mitotic progression

Mitotic events play a fundamental role in normal and diseased cells. PAKs are critical at many levels during mitosis. Overexpression of constitutively activated PAK1—a physiologically relevant setting because PAK1 is hyperactivated in cancer—leads to the formation of spindles and mitotic defects (Li et al., 2002). Once PAK1 is on the centrosome, GIT1 stimulates its kinase, and in turn, PAK1 phosphorylates Aurora-A-Thr215/Ser288/Ser342 and regulates centrosome maturation (Zhao et al., 2005). PAK1 phosphorylation of histone H3.3A/H3-Ser10 is thought to be involved in the condensation of chromosomes during mitosis. As opposed to PAK1, PAK2 phosphorylation of histone H4 of Ser47 helps its interaction with histone H3.3 during replication (Kang et al., 2011). Similarly, PAK2 signaling has also been shown to participate in the organization of mitotic spindles (Nekrasova and Minden, 2011; Bombard et al., 2013).

As the process of mitosis is affected by microtubule, PAK1 signaling also regulates astral microtubules during mitosis (Banerjee et al., 2002). PAK1 signaling affects both polymerization and depolymerization of microtubule dynamics: PAK1 phosphorylates Tubulin Cofactor B on Ser65 and Ser128 and facilitates microtubule polymerization (Vadlamudi et al., 2005a), and PAK1 phosphorylation of mitotic centromere-associated kinesin on Ser192 and Ser111 promotes microtubule depolymerization (Pakula et al., 2012). In addition, PAK1 phosphorylation of ArpC1b-Thr21, a component of the Arp2/3 complex, leads to defective centrosome duplication (Vadlamudi et al., 2000). Interestingly, ArpC1b-Thr21 can also be phosphorylated by Aurora-A, which itself is a substrate of PAK1 (Molli et al., 2010). Similarly, Aurora-A phosphorylates mitotic centromere-associated kinesin (Zhang et al., 2008; Braun et al., 2014). Polo-like kinase 1 is another important substrate of PAK1 during mitosis (Maroto et al., 2008). The current working model suggests that interactions among the PAK1, Aurora-A, ArpC1b, mitotic centromere-associated kinesin, and Polo-like kinase 1 might be important for the regulation of cell cycle in the mitotic phase.

7. PAKs and steroid receptors

Being a kinase, PAK1 phosphorylates Ser305 of estrogen receptor-α (ER) and modulates its transcriptional activities in a ligand-independent manner (Wang et al., 2002; Rayala et al., 2006a, 2006b; Tharakan et al., 2008). Because ER is transactivated by PAK1 in the absence of estrogen, the breast cancer cells show resistance to anti-estrogenic agents such as tamoxifen (Rayala et al., 2006a, 2006b; Bostner et al., 2007). In this context, ER-positive breast cancer patients with nuclear localization of PAK1 were shown to be tamoxifen insensitive (Holm et al., 2006). In contrast to PAK1, PAK2 interacts androgen receptor (AR) and redistributes to the nucleus, which inhibits the ability of androgen receptor to inhibit its target genes (Yang et al., 2001). Interestingly, PAK6 also interacts with AR, and AR-Ser578 phosphorylation by PAK6 is also accompanied by AR degradation in a ligase-dependent manner (Liu, X., et al., 2013; Liu, L., et al., 2013; Liu, T., et al., 2013).

8. PAKs in DNA damage response

The PAK signaling was initially linked to DNA-damage response (DDR) by an observation that ionizing radiation (IR) stimulates PAK2 activity in leukemia cells (Roig and Traugh, 1999). This was followed by the finding that PAK1 signaling regulates the expression of a large number of IR-regulated genes in the DNA repair pathway (Motwani et al., 2013). Further, PAK1 modulates the degree of DNA-damage response via directly phosphorylating microchirida CW-type zinc finger 2 (MORC2-Ser739) and add inducing colocalization with γH2AX (Li, D.Q., et al., 2012; Li, Y., et al., 2012). In addition to radiation, PAK1 is stimulated by genotoxic therapeutic agents such as etoposide, and in-turn, PAK1 phosphorylates CAF1-Ser338 and causes radio-resistance (Adaini et al., 2015). In general, PAK activation confers survival advantage to cancer cells against DNA-damaging agents, and hence, targeting PAKs has been thought as potential therapeutic approach to sensitize target cells in radiotherapy.

9. PAKs cross-talk with ErbB2 signaling

ErbB2 overexpression and hyperactivation is a prevalent event in breast tumors and a large number of other solid tumors. In breast cancer cells, stimulation of ErbB2 by heregulin-b1 activates PAK1 kinase, which in turn causes growth factor-mediated increased motility and invasion of breast cancer cells (Adam et al., 1998). In addition, PAK1 signaling also phosphorylates β-catenin on Ser675 (Zhao et al., 2012) and Ser663 (Park et al., 2012), stimulating β-catenin’s transcriptional activity (Park et al., 2012). As PAK1 phosphorylates β-catenin and both PAK1 and β-catenin are downstream effectors of ErbB2 signaling (Adam et al., 1998; Wang et al., 2006; Ding et al., 2005), PAK1 connects ErbB2 signaling with β-catenin in breast tumor cells (Arias-Romero et al., 2013). Interestingly, PAK4 also phosphorylates β-catenin-Ser675 and stimulates the transcriptional activity of TCF/LEF (Li, D.Q., et al., 2012; Li, Y., et al., 2012). In addition to regulating the invasiveness, ErbB2-PAK1 axis supports ErbB2 regulation of vascular endothelial growth factor and this could be inhibited by Herceptin targeting of ErbB2 (Bagheri-Yarmand et al., 2000). In addition, the process of angiogenesis has been also shown to be suppressed by inhibiting PAK functions (Kiosses et al., 2002). Further PAK1 signaling is stimulated by Angiopoietin-1 via regulatory interactions among Dok, Nck, and Tek receptors in endothelial cells (Master et al., 2001). Another PAK1 target that has role in vascular system is Tie1 endothelial receptor tyrosine kinase Thr794 (Reinardy et al., 2015). Consistent with co-regulatory nature of PAK1 and ErbB2 axis in breast cancer, a recent large-scale phosphoproteomic study of breast cancer specimens found that ErbB2 overexpression closely correlates with activated PAK1 in addition to other kinases (Mertins et al., 2016). In brief, ErbB2-PAK1 axis may regulate many facets of signaling in breast cancer, and perhaps, in other hormone-regulated cancers.

10. PAKs and the nervous system

The PAK family plays an important role in a number of neuronal processes, ranging from cytoskeletal remodeling, neuronal apoptosis,
axonal guidance, neuronal polarity, synaptic activity, dendritogenesis, to spinal maintenance. The role of PAKs in the nervous system can be traced back to the role of PAK4 in neural tube development in embryos, as PAK4-knockout mice showed defects in axonal growth and neuronal development (Qu et al., 2003). PAK1 signaling participates in brain development because of its ability to induce neuronal migration in select areas of the cortex (Pan et al., 2015). Netrin-1 chemorepellant modulates the growth of axonal cones in a PAK1 signaling-dependent manner where PAK1 phosphorylation of shootin1 facilitates the coupling of F-actin dynamics with the formation of motile structures (Toriyama et al., 2013). Similarly, neuronal cell adhesion molecule (NCAM) stimulation of PAK1 activity supports actin polymerization during neuronal differentiation (Li, D. et al., 2013; Li, S. et al., 2013; Li, Y. et al., 2013). In contrast to Netrin-1 and NCAM, endogenous Ncischarin suppresses neurite outgrowth by inhibiting PAK1 and PAK2 phosphorylation (Ding et al., 2015). PAK1 pathway also regulates the process of dendritogenesis and spine formation by influencing actin remodeling (Hayashi et al., 2007). In this context, PAK1 signaling participates in the dendritic spine maintenance via phosphorylation of myosin light chain and Cofilin (Rubio et al., 2012). Interestingly, targeting PAK1 pathway in cerebellar granule neurons mimics the effect of FOXO transcriptional factors on neuronal morphology. Since this can be rescued by PAK1, it suggests a potential role of FOXO regulation of PAK1 in neuronal biology (de la et al., 2010). Studies from PAK1-knockout mice suggest that PAK1 signaling contributes to long-term potentiation and synaptic plasticity in hippocampus, presumably, due to the effects of its downstream substrate(s) (Asrar et al., 2009; Kelly and Chernoff, 2012). Studies from PAK1 and PAK3-knockout mice suggest that the ability of PAK to regulate neuronal plasticity and synaptic activities play an important role in the size and growth of brain (Huang et al., 2011; Kelly and Chernoff, 2012).

Because of an inherent role of the PAK family in the neuronal biology, it is not surprising that dysregulation of PAKs and their downstream substrates are associated with a number of brain disorders (Chan and Manser, 2012; section on PAK3 this review). For example, low levels of PAK1 and PAK3 mRNAs were seen in the brains of individuals with depression (Fuchsova et al., 2016). The relevance of PAK signaling in neuronal biology is also evident from the observation that inhibition of PAK activity provides neuroprotective effects and accelerates restoration of spinal cord functions in a murine model of spinal cord injury (Ji et al., 2016). Similarly, PAK6 is upregulated following spinal cord injury in a rat model (Zhao et al., 2011), and it interacts with leucine-rich repeat kinase 2 (LRRK2), which was previously shown to be involved in Parkinson’s disease (Civiero et al., 2015). In addition, defects in the PAK pathway have been linked to Alzheimer’s disease (AD) (Arsenault et al., 2013; Zhao et al., 2006). PAK expression studies in specific hippocampus regions of AD individuals show an increase in PAK expression in early stages of the disease followed by decreased expression in severe subjects (Nguyen et al., 2008). There are also indications that mutants of the amyloid precursor protein pathway interacts with PAK3 during apoptosis of neurons in familial Alzheimers (McPhie et al., 2003). All these clearly point to the fact that targeting the PAK pathway has potential therapeutic advantages for neurodegenerative diseases. In this context, more recently, chemical inhibition of PAK1 prevented accumulation of F-actin at the disruption of myelin junctions as well as normalized myelin permeability in a murine model of hereditary neuropathy, raising the possibility of targeting PAK pathway in diseases associated with demyelination (Hu et al., 2016).

11. PAKs and the heart

PAK signaling is central to normal and diseased cardiac physiology because of its effects on ion channels, sarcomeric proteins, and excitation and contraction. Results from knockout mice support the notion that PAK1 may be essential for cardiac growth and optimal functioning, which is associated in part with its ability to regulate calcineurin signaling (Davis et al., 2015; Kelly and Chernoff, 2012). Similarly, studies from PAK4-knockout mice show an essential role in actin remodeling in cardiomyocytes, and in the development of various compartments of heart (Nekrasova and Minden, 2012; Kelly and Chernoff, 2012). In a zebrafish model of heart injury, targeting PAK1 has been shown to impair the growth of cardiomyocytes, while targeting PAK4 was found to affect cardiovascular regeneration, highlighting the significance of PAKs in the heart (Peng et al., 2016; Tian et al., 2009; Qu et al., 2003). Mechanistically, the ability of PAK1 to modulate the activity of protein phosphatase PP2A and affect Ca ++ homeostasis plays a major role in cardiac physiology. Antagonizing beta-adrenergic and hypertrophic stress and exerting cardiac protective effects by PAK1 signaling involve activation of protein phosphatase 2A (PP2A) (Sheehan et al., 2007; Taglieri et al., 2011). The PAK1 kinase-dependent interaction with PP2A potentiates PP2A subunit assembly and activation (Staer et al., 2013). PAK1 signaling also regulates Ca ++ homeostasis via sarcoplasmic reticulum Ca ++-ATPase type 2a (SERCA2a) expression (Wang et al., 2014; Wang, Y. et al., 2014). These observations led to the notion that PAK1 is a therapeutic target to treat stress-induced cardiac hypertrophy. Experiments are ongoing and some have been tested in murine models using a synthetic PAK1 activator (Liu et al., 2011).

12. PAK1 and PAK4 in cancer progression

Among PAK family members, PAK1 and PAK4 are mostly upregulated in human cancers. In general, elevated PAK expression and its kinase activity support a variety of cancerous phenotypes and correlates well with the progression to more invasiveness. As we had summarized PAK1 overexpression in cancer (Kumar et al., 2006; Kumar and Li, 2016), here will limit our discussion to PAK4. Like PAK1 in human cancer, overexpression of PAK4 also correlates with poor prognosis, tumor aggressiveness (Li, D. et al., 2015; Begum et al., 2009), metastasis, and infiltration (Song et al., 2015). PAK4 is upregulated in pancreatic cancer, endometrioid ovarian cancer, basal-like breast cancer, and oral squamous cell carcinoma (Begum et al., 2009; Mahlamaki et al., 2004; Davis et al., 2013; Chen et al., 2008; Jiang et al., 2016). PAK4 upregulation in cancer cell lines lead to an increased cell survival, anchorage-independent growth, and transformation in experimental models (Liu et al., 2008; Menzel et al., 2008). In general, PAK4 overexpressing cancer cells are sensitive to growth inhibition by its depletion (Davis et al., 2013; Ahn et al., 2011; Kimmelman et al., 2008; Callow et al., 2002), suggesting an important role for PAK4-driven pathways. There are also examples of mutations that activate PAK4 kinase in certain cancers (Greenman et al., 2007; Whale et al., 2013; Parsons et al., 2005) but such mutations await functional validation. PAK4 signaling supports the growth of cancer cells through AKT- and ERK-regulated signaling (Tyagi et al., 2014; Tabusa et al., 2013). PAK4 modulation of CRAF and BAD phosphorylation inhibits apoptosis in endothelial cells (Alavi et al., 2003). The biology of PAK4 overexpressing cancer cells has also been shown to be regulated by PAK4 targeting by miR-199a-5p (Hou et al., 2011), miR-433 (Xue et al., 2015), and miR-224 (Li et al., 2014) in hepatocellular carcinoma cells. PAK4 also phosphorylates Smad2 on Ser465 in growth factor-stimulated cancer cells (Wang, C. et al., 2014; Wang, Y. et al., 2014). PAK4 is also a Met-receptor-signaling integrator that confers invasive phenotypes (Paliouras et al., 2009). Furthermore, PAK4 interaction with DGR8L leads to an increased LIMK1 expression and increased motility of gastric cancer cells (Li, X. et al., 2010), and modulation of MMP expression in certain cancer cell types (Wang et al., 2013; KesanaKurti et al., 2012; Jiang et al., 2016). PAK4 also control the dynamics of cell-adhesion turnover by protecting RhoI from ubiquitination (Dart et al., 2015).

13. PAK2 biology

As oppose to PAK1 and PAK3, Puk2-knockout is embryonic lethal in mice (Hofmann et al., 2004; Kelly and Chernoff, 2012). Upstream
activators of the PKA2 activity include transforming growth factor β (Wilkes et al., 2003), alpha2-macroglobulin binding to GRP78 (Misra et al., 2005) and AMP-activated protein kinase (Banko et al., 2011), while miR-137 regulate expression of PKA2 (Hao et al., 2015). PKA2 phosphorylation of merlin-Ser518 affects tumor suppressive function (Rong et al., 2004). c-Jun-Thr2/Thr8/Thr89/Thr93/Thr286 alter growth regulatory pathways (Li et al., 2011a), Caspase-7-Ser30/Thr173/ Ser239 modulates apoptosis (Li et al., 2011b), Paxillin-Ser272/Ser274 modulates protease activation (Lee et al., 2013), and STAT5-Ser779 regulates leukemogenesis (Berger et al., 2014). PKA2 signaling also interacting with c-Myc pathway; c-Myc-Thr358/Ser373/Thr400 phosphorylation antagonizes the ability of c-Myc to stimulate its target genes while Pak2 knockdown upregulates c-Myc in monocytes (Huang et al., 2004; Zeng et al., 2015). Interestingly, cellular stress such as hyperosmotic shock (Chan et al., 1999), ultraviolet light (Tang et al., 1998), and ionizing radiation (Roig et al., 1999) cleave Pak2 in a caspase-dependent manner, contributing to apoptosis in a variety of cell-types. More recently, insulin signaling has been shown to inhibit Pak2 activity, which leads to an increase in GLUT4-mediated uptake of glucose in neuronal cells (Varshney and Dey, 2016).

14. PKA3 biology

PKA3 is predominantly expressed in the nervous system, and is stimulated by Cool-2, Dbl, Cdc42 (Bagrodia et al., 1998; Bagrodia et al., 1999), while GTPase-dependent stimulation of PKA3 is inhibited by p50 (Cool-1) (Bagrodia et al., 1998). PKA3 plays an important role in synapse plasticity (Boda et al., 2004). In this context, PKA3 phosphorylation of AMPA excitatory receptor subunit GluA1, involved in synaptic functions, on Ser863 regulates receptor trafficking in cortical neurons (Hussain et al., 2015). Because AMPAR receptors are important in synaptic plasticity, PKA3-AMPAR signaling has been suggested to be involved in cognition function. A point mutation in PKA3 gene is intimately linked to a form of mental retardation (Allen et al., 1998). Further, a hemizygous PKA3 variant has been identified as a putative disease-linked gene for Cerebral palsy (McMichael et al., 2015). More recently, PKA3 has been shown to functionally interact with Scribble, a signaling protein with a role in the physiology of forgetting in Drosophila, as a component of forgetting signalosome, and participate in the regulation of forgetting (Cervantes-Sandoval et al., 2016). Consistent with a predominantly neuronal functional role, Pak3-deficient mice have a compromised late term potentiation response and memory retention (Meng et al., 2005). These phenotypes are similar to Pak1-knockout mouse, which is viable but suffers from defects in the immune, neuronal, and metabolic systems (Arias-Romero and Chernoff, 2008). However, deletion of both Pak1 and Pak3 genes in mice leads to stronger defect in memory and learning (Huang et al., 2011).

15. PKA5/7 biology

PKA5, also known as PKA7, is upregulated by Aurora-A (He et al., 2014) and downregulated by miR-129 and miR-186 in certain cancer cells (Zhai et al., 2015; Zheng et al., 2015). Studies from Pak5-knockout mice show PAK5 has roles in mobility, learning, and memory related functions (Nekrasova, 2008; Kelly and Chernoff, 2012; Furnari et al., 2013). In addition, PKA5 is also believed to be involved in synaptic plasticity because of its coexpression with a psychosis risk gene DISC1 (Morris et al., 2014). Neuronal function of PKA5 may be associated with its ability to phosphorylate two critical regulators of synaptic vesicle trafficking, the Pasc1-1 and Synaptophysin-1 (Strohle et al., 2012). PKA5-dependent cytoskeletal remodeling also contributes to neurite development and this may involve suppression of Rho activation (Wu and Frost, 2006; Dan et al., 2002). The level of PKA5 is high in many cancers (Kumar and Li, 2016) including liver (Fang et al., 2014), esophageal (He et al., 2016), and gastric cancer (Gu et al., 2013). There are also examples of gain-of-function PKA5 mutations in small number of lung tumors (Fawdar et al., 2013). PKA5 phosphorylation of BAD on Ser112 inhibitors apoptosis (Cotteret et al., 2003; Wang et al., 2010). PKA5 phosphorylation of GATA-1 on Ser161 and Ser187 causes epithelial-to-mesenchymal transition in breast cancer cells, phosphorylation of E47 on Ser39 promotes colon cancer metastasis (Li, Y. et al., 2015; Zhu et al., 2016), and phosphorylation of p120-catenin-Ser288 facilitates cytoskeleton reorganization with implications in cancer cell motility and invasion (Wong et al., 2010).

16. PKA6 biology

The PKA6 is unique among PKA family as it is positively regulated by androgen receptor but not Rac or Cdc42 (Lee et al., 2002; Liu, X., et al., 2013; Liu, L., et al., 2013; Liu, T., et al., 2013). PKA6 may also be involved in stress-signaling as it is stimulated by p38-MAP kinase (Kaur et al., 2005). Expression of PKA6 is targeted by miR-328 and miR-23a in prostate cancer cells (Liu et al., 2015; Cai et al., 2015), and by miR-429 in colon cancer cells (Tian et al., 2015). PKA6 interacts with the cell junction protein IQGAP1 in a kinase activity-dependent manner and regulates the dissociation of cell-cell junctions in growth factor-stimulated cells (Fram et al., 2014; Morse et al., 2016). PKA6 phosphorylates AR (Ser578 (Liu, X. et al., 2013), Ser308, Ser346, Ser360, Thr326 and Thr354 (Liu, J. et al., 2013), MDM2 (Thr158 and Ser186) (Liu, X. et al., 2013), and LIMK1 (Thr508) (Cai et al., 2015) in prostate cancer cells and is involved in cell growth and migration. PKA6 phosphorylates androgen receptor on Ser-578 and marks its degradation via E3 ligase-Mdm2 pathway (Liu, X., et al., 2013; Liu, L., et al., 2013; Liu, T., et al., 2013). Interestingly, PKA6 phosphorylation of Mdm2 on Thr-158 and Ser-186 drives AR ubiquitin-mediated degradation.

Genetic studies suggest that Pak6 deletion in mice leads to a gain in the body weight (Furnari et al., 2013), while combined deletion of Pak5/6 and Pak6 genes leads to a significant impairment of mobility, memory, and learning as compared to deletion of individual genes (Nekrasova, 2008; Furnari et al., 2013). As PKA6 is predominantly expressed in the brain, PKA6 has been recognized as a therapeutic candidate gene for epileptic encephalopathy (Oliver et al., 2016). PKA6 is upregulated in colon cancer (Chen et al., 2015), hepatocellular carcino- ma (Chen et al., 2014), and prostate cancer (Kaur et al., 2008; Wen et al., 2009). However, PKA6 downregulation in clear renal cell carcinoma is associated with unfavorable survival of patients (Liu et al., 2014). In human therapeutic treatments, PKA6 upregulation promotes resistance to 5-fluorouracil treatment in colon cancer patients (Chen et al., 2015), and its inhibition enhances the sensitivity of prostate cancer cells to radiation (Zhang et al., 2010) and docetaxel (Wen et al., 2009).

17. PKAs as modifiers of therapeutic sensitivity

Beginning from the initial demonstration of a critical role for PKA1 in breast cancer, by acting downstream of ErbB2 and promoting aggressiveness, and a widespread observation of PKAs overexpression in human cancer, PKAs have emerged as bona-fide therapeutic targets for cancer. The first generation was PKA inhibitors, which were directed against the ATP-binding domain, and led to the development of ATP-competitive inhibitors, i.e., K252a and CEP-1347 (Kaneko et al., 1997; Nheu et al., 2002), or OSU-03012 (Zhu et al., 2004). One such ATP-competitive PKA inhibitor PF-3758309, originally designed as a PKA4 inhibitor, targets both group I and II PKAs as well as other off-target kinases, advanced into Phase I clinical trials (Murray et al., 2010). However, PF-3758309 was eventually withdrawn from clinical use. It may be because of their undesirable pharmacological properties such as drug efflux (Bradshaw-Pierce et al., 2013). More recently, a derivative of FRAX-597, the FRAX-1306, has been shown to have high selectivity against PKA4, but may also have off-target receptor tyrosine kinases (Ong et al., 2015). Similarly, another PKA1 inhibitor IPA3 was found to be not
suitable for clinical use, but now serves as a good tool to dissect the intricacies of PAK1 signaling in model systems (Singhal and Kandel, 2012). A newer generation of PAK1-specific inhibitors, such as G-5555, are being developed and tested in PK/PD studies (Ndubaku et al., 2015).

High levels of PAKs cause better cell survival, hence render cancer cells resistance to chemotherapeutic drugs. For example, overexpression of PAK1 confers chemo-resistance to PI-3K inhibitors in colon cancer (Qing et al., 2012) and B-cell lymphomas (Walsh et al., 2013), and resistance to MET inhibitors in pancreatic cancer cells (Zhou et al., 2014). Similar to PAK1, upregulation of PAK4 promotes insensitivity to chemotherapies such as doxorubicin or paclitaxel (Park et al., 2013), cisplatin (Shu et al., 2015; Fu et al., 2014) in different cancer types, and gemcitabine in cancer cells (Moon et al., 2015). Likewise, PAK5 overexpression confers resistance to paclitaxel (Li, D. et al., 2013; Li, S. et al., 2013; Li, Y. et al., 2013) and cisplatin in cancer cells (He et al., 2014; Zhang et al., 2015). PAK1 and PAK6 overexpression promotes therapeutic resistance to 5-fluorouracil in some patients (Huyhn et al., 2016; Chen et al., 2015). These representative examples highlight the potential use of PAK-inhibitors in cancer chemotherapies to reverse resistance. Collectively, these observations catalyzed the development of PAK-inhibitor drugs, and advanced structure-functional studies to refine effectiveness and selectivity. Nevertheless, one must take a cautious approach because PAK signaling has profound effect in cells; ErbB3, an upstream activator of PAKs, has vital roles in organs such as the hear. Hence, potential side effects may be inherent of targeting PAKs for therapy. With ongoing intense pharmacokinetics and toxicology studies yield promising results in animal models, the authors hope that these issues will be resolved and PAK inhibitors are likely to be used in future in combination with other therapeutic agents.

18. Future of PAKs

Since the initial finding of PAKs as downstream effectors of small GTPases over twenty years ago, the field of PAK research has made significant advances in both mechanistic and functional studies. More of these studies in the future are likely to shape a better understanding of PAKs. Our appreciation for the role of PAKs in vast number of human diseases such as cancer (Kumar and Li, 2016), inflammation (Dammann et al., 2014), neurological disorders (Ma et al., 2012), cardiovascular disorders (Ke et al., 2014), and viral diseases (Van den Broeke et al., 2013) is likely to grow. The breadth and scope of developing and improving next generation PAK modifiers and their utilization as a combination setting with other anti-cancer agents will likely gain momentum and may extend to many diseases.

The authors see further insights into co-expressing PAKs in tumor specimens, an atlas of co-regulated PAK-intracellular signaling networks within the context of selective or shared effector substrates, aligning specific arms of the PAKs cytoplasmic signaling with the nuclear arms, discovering new PAK nuclear functions, and further refinement of PAK inhibitors. It will be important to learn more about the functions of spliced PAK transcripts, if any. Given that there is an emerging importance for non-coding RNAs in cancer, the authors hypothesize that PAK’s non-coding RNA transcripts will influence the biology of PAK proteins.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Acknowledgments

This review and the corresponding Gene Wiki article are written as part of the Gene Wiki Review series—a series resulting from a collaboration between the journal GENE and the Gene Wiki Initiative. The Gene Wiki Initiative is supported by National Institutes of Health (GM089820). Additional support for Gene Wiki Reviews is provided by Elsevier, the publisher of GENE. The authors are sorry for not citing the work of many of our colleagues due to space limitations. The authors thank their numerous trainees for their work and contributions to the authors’ laboratories over the years, and Dr. Xiaodong Li for his outstanding effort to prepare the figures. Over the years, PAK signaling studies in Rakesh Kumar laboratory have been supported by the National Institutes of Health grant CA090970, and Research in Feng Li laboratory is supported by the National Natural Science Foundation of China, Number 31371424 and 31571457. Rahul Sanawar is supported by a Research Fellowship from the University Grants Commission Award number 23/06/2013/((EU)). The corresponding Gene Wiki entry for this review can be found here.

References


Abo, A.A., et al., 1998. PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filipodia. EMBO J. 17, 6527–6540.


Basakaran, Y., et al., 2012. Grop9 and 11 mammalian PAKs have different modes of activa-

R. Kumar et al. / Gene 605 (2017) 20–31

Berger, A., Hoelbl-Kovacic, A., Bourgeais, J., Hoe, U. S. A. 110, 12426


Wangs, et al., 2014b. Pak1 is required to maintain ventilatory Ca2+ homeostasis and electrophysiological stability through SERCA2a regulation in mice. Circ. Arrhythm. Electrophysiol. 7, 938–948.
Wang, S.E., et al., 2006. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. Cancer Res. 66, 9591–9600.
Wang, C., et al., 2014b. Pak1 is required to maintain ventilatory Ca2+ homeostasis and electrophysiological stability through SERCA2a regulation in mice. Circ. Arrhythm. Electrophysiol. 7, 938–948.
Wang, S.E., et al., 2006. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. Cancer Res. 66, 9591–9600.
Wang, C., et al., 2014b. Pak1 is required to maintain ventilatory Ca2+ homeostasis and electrophysiological stability through SERCA2a regulation in mice. Circ. Arrhythm. Electrophysiol. 7, 938–948.